<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36864661</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.</ArticleTitle><Pagination><StartPage>2557</StartPage><EndPage>2569</EndPage><MedlinePgn>2557-2569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad059</ELocationID><Abstract><AbstractText>Pathologies that are causative for neurodegenerative disease (ND) are also frequently present in unimpaired, older individuals. In this retrospective study of 1647 autopsied individuals, we report the incidence of 10 pathologies across ND and normal ageing in attempt to clarify which pathological combinations are disease-associated and which are ageing-related. Eight clinically defined groups were examined including unimpaired individuals and those with clinical Alzheimer's disease, mixed dementia, amyotrophic lateral sclerosis, frontotemporal degeneration, multiple system atrophy, probable Lewy body disease or probable tauopathies. Up to seven pathologies were observed concurrently resulting in a heterogeneous mix of 161 pathological combinations. The presence of multiple additive pathologies associated with older age, increasing disease duration, APOE e4 allele and presence of dementia across the clinical groups. Fifteen to 67 combinations occurred in each group, with the unimpaired group defined by 35 combinations. Most combinations occurred at a &lt;5% prevalence including 86 that were present in only one or two individuals. To better understand this heterogeneity, we organized the pathological combinations into five broad categories based on their age-related frequency: (i) 'Ageing only' for the unimpaired group combinations; (ii) 'ND only' if only the expected pathology for that individual's clinical phenotype was present; (iii) 'Other ND' if the expected pathology was not present; (iv) 'ND + ageing' if the expected pathology was present together with ageing-related pathologies at a similar prevalence as the unimpaired group; and (v) 'ND + associated' if the expected pathology was present together with other pathologies either not observed in the unimpaired group or observed at a greater frequency. ND only cases comprised a minority of cases (19-45%) except in the amyotrophic lateral sclerosis (56%) and multiple system atrophy (65%) groups. The ND + ageing category represented 9-28% of each group, but was rare in Alzheimer's disease (1%). ND + associated combinations were common in Alzheimer's disease (58%) and Lewy body disease (37%) and were observed in all groups. The Ageing only and Other ND categories accounted for a minority of individuals in each group. This observed heterogeneity indicates that the total pathological burden in ND is frequently more than a primary expected clinicopathological correlation with a high frequency of additional disease- or age-associated pathologies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Sharon X</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baer</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>EunRan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-5599-5098</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuck</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-4589-1180</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115139</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2023 May 08;:</RefSource><PMID Version="1">37150902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="Y">Multiple System Atrophy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Lewy body disease</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36864661</ArticleId><ArticleId IdType="pmc">PMC10232273</ArticleId><ArticleId IdType="doi">10.1093/brain/awad059</ArticleId><ArticleId IdType="pii">7067885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Irwin DJ, Grossman M, Weintraub D, et al. . Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol. 2017;16:55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181646</ArticleId><ArticleId IdType="pubmed">27979356</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, et al. . Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181&#x2013;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Richardson H, Xie SX, et al. . The development and convergence of co-pathologies in Alzheimer&#x2019;s disease. Brain. 2021;144:953&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041349</ArticleId><ArticleId IdType="pubmed">33449993</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanth S, Nelson PT, Katsumata Y, et al. . Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77:1299&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309572</ArticleId><ArticleId IdType="pubmed">32568358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Whitwell JL, Tosakulwong N, et al. . The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging. 2019;77:26&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486870</ArticleId><ArticleId IdType="pubmed">30776649</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;zel E, Ziegler G, Berron D, et al. . Amyloid pathology but not APOE &#x3b5;4 status is permissive for tau-related hippocampal dysfunction. Brain. 2022;145:1473&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128811</ArticleId><ArticleId IdType="pubmed">35352105</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, W&#xf6;hrer A, et al. . Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol (Berl). 2013;126:365&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Aakre JA, Knopman DS, et al. . Prevalence and heterogeneity of cerebrovascular disease imaging lesions. Mayo Clin Proc. 2020;95:1195&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316133</ArticleId><ArticleId IdType="pubmed">32498775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. . Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: The Hisayama study. Acta Neuropathol (Berl). 2003;106:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904992</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(Pt 10):3005&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470712</ArticleId><ArticleId IdType="pubmed">23065790</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, Farlow MR, Unverzagt FW, et al. . The tauopathy associated with mutation +3 in intron 10 of tau: Characterization of the MSTD family. Brain. 2008;131::72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical features of Alzheimer disease with and without Lewy bodies. JAMA Neurol. 2015;72:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501861</ArticleId><ArticleId IdType="pubmed">25985321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2018;6:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yang J, Yu L, et al. . Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140:804&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837473</ArticleId><ArticleId IdType="pubmed">28082297</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. . National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol (Berl). 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Collaborating Centre for Chronic Conditions (UK) . Parkinson&#x2019;s disease: National clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, UK; 2006. Accessed 11 November 2022. http://www.ncbi.nlm.nih.gov/books/NBK48513/</Citation><ArticleIdList><ArticleId IdType="pubmed">21089238</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology research group on neuromuscular diseases and the El Escorial &#x201c;Clinical Limits of Amyotrophic Lateral Sclerosis&#x201d; workshop contributors. J Neurol Sci. 1994;124(Suppl):96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Van Deerlin VM, Lee EB, et al. . A platform for discovery: The University of Pennsylvania integrated neurodegenerative disease biobank. Alzheimers Dement J Alzheimers Assoc. 2014;10:477&#x2013;484.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel Det al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692704</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MSet al. . Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies. J Neuropathol Exp Neurol. 2008;67:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Boeve BF, Dickson DWet al. . Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89:88-100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrobot OA, Attems J, Esiri M, et al. . Vascular cognitive impairment neuropathology guidelines (VCING): The contribution of cerebrovascular pathology to cognitive impairment. Brain. 2016;139:2957&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">27591113</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Richardson H, Xie SXet al. . Cerebrovascular disease lesions are additive and tied to vascular risk factors and cognitive impairment. FreeNeuropathol. 2022;3:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10209856</ArticleId><ArticleId IdType="pubmed">37250748</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, et al. . Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol (Berl). 2015;130:363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Perrin RJ, Franklin EE, et al. . Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathol Off J Jpn Soc Neuropathol. 2015;35:390&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521391</ArticleId><ArticleId IdType="pubmed">25964057</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, et al. . Concurrence of &#x3b1;-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl). 2002;104:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12070658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ, Khatun A, Coomans E, et al. . Relevance of biomarkers across different neurodegenerative diseases. Alzheimers Res Ther. 2020;12:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222479</ArticleId><ArticleId IdType="pubmed">32404143</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wang T, Yu L, et al. . To what degree is late life cognitive decline driven by age-related neuropathologies? Brain. 2021;144:2166&#x2013;2175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8370442</ArticleId><ArticleId IdType="pubmed">33742668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol (Berl). 2017;134:171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, La Joie R, Petersen C, et al. . Comorbid neuropathological diagnoses in early versus late-onset Alzheimer&#x2019;s disease. Brain. 2021;144:2186&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8502474</ArticleId><ArticleId IdType="pubmed">33693619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Fujiwara H, Mann DM, et al. . Lewy Bodies contain altered alpha-synuclein in brains of many familial Alzheimer&#x2019;s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853391</ArticleId><ArticleId IdType="pubmed">9811326</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenoven I, Aarsland D, Weintraub D, et al. . Cerebrospinal fluid Alzheimer&#x2019;s disease biomarkers across the spectrum of Lewy body diseases: Results from a large multicenter cohort. J Alzheimers Dis JAD. 2016;54:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535729</ArticleId><ArticleId IdType="pubmed">27567832</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, et al. . Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Corrada MM, Kovacs GG, et al. . Non-Alzheimer&#x2019;s contributions to dementia and cognitive resilience in the 90+ study. Acta Neuropathol (Berl). 2018;136:377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6534149</ArticleId><ArticleId IdType="pubmed">29916037</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanth SD, Schmitt FA, Nelson PT, et al. . Four common late-life cognitive trajectories patterns associate with replicable underlying neuropathologies. J Alzheimers Dis. 2021;82:647&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316292</ArticleId><ArticleId IdType="pubmed">34057090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Trojanowski JQ, et al. . TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70:1418&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830649</ArticleId><ArticleId IdType="pubmed">24080705</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong Net al. . Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JBet al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer Get al. . Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer&#x2019;s disease. Acta Neuropathol (Berl). 2016;131:659&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835512</ArticleId><ArticleId IdType="pubmed">27062261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA. Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery. PLoS Med. 2017;14:e1002256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349649</ArticleId><ArticleId IdType="pubmed">28291788</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>